Newsroom.
GC Biopharma Initiates Voluntary Market Withdrawal of One Lot of Product
Teaneck, NJ, December 16, 2025
As a precautionary measure, GC Biopharma Corporation is initiating a voluntary market withdrawal of the following lot due to the potential for an increased rate of hypersensitivity reactions associated with this specific lot. Hypersensitivity reactions are a known risk with immune globulin products.
Alyglo® (immune globulin intravenous, human-stwk) 10% Liquid
NDC Number: 61476-104-20
Lot Number: 394C24030
Packaging Size: 20g/200mL
Expiration Date: October 1, 2027
- Please examine your stock immediately to identify inventory on hand, in transit, and at patient sites.
- Immediately quarantine Lot 394C24030.
- If you have product from this lot, please cease use immediately and do not dispense from this lot.
- Return the affected product to the point of purchase to receive replacement product. Your GC Biopharma representative can assist with the return process.
If you have any technical or clinical questions or to report an adverse event, please contact Dr. Alan Huber, GC Biopharma US Medical Affairs at gcmedicalaffairs@gcbiopharmausa.com or 1-833-426-6426.
©2025 GC Biopharma USA, Inc. All rights reserved.
All trademarks are the property of their respective owners.
